Sonia

At a glance

Pricing

~$20/mo.

HIPAA

Not disclosed

SOC 2

Not disclosed

EHRs

—

Founded

—

Bottom line

Voice-based AI therapist with 6-week GAD program.

Free tier available.

Overview

Pricing

What it costs

Free tier only; no paid plans publicly disclosed.

Source: vendor pricing page. Verified May 23, 2026.

Peer-reviewed coverage

What the literature says

5 peer-reviewed studies indexed on PubMed evaluate Sonia in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.

Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.

Wortelboer N, Kent S, Konings IR, et al.· Eur J Cancer· 2025RCT

The SONIA phase 3 trial demonstrated adding cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) to first-line endocrine therapy (aromatase-inhibitor) was not superior in terms of progression-free survival after two treatment lines compared to addition to second-line (fulvestrant) in patients with hormone-receptor positive, HER2-negative advanced breast cancer. Although critical to inform decision-making, a detailed health economic evaluation of both treatment strategies is currently lacking. We estimated the cost-effectiveness of CDK4/6i use in first- versus second-line over 5 years using pa…

Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.

Wortelboer N, Kent S, Blommestein HM, et al.· J Natl Cancer Inst· 2026RCT

The SONIA trial demonstrated that addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) to first-line endocrine therapy (aromatase-inhibitor) was not superior in terms of progression-free survival after 2 treatment lines compared with addition to second-line (fulvestrant), while first-line use increased toxicity (74% more grade ≥3 adverse events) and costs. Understanding the impact of both treatment strategies on health-related quality of life (HRQOL) is critical to inform patient-centered treatment decisions. HRQOL was assessed using the Functional Assessment of Cancer Ther…

Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.

Jin X, Li Z· Front Pharmacol· 2025

The optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly in resource-limited settings such as China. This study evaluated the cost-effectiveness of first-line versus second-line CDK4/6 inhibitor use based on the SONIA trial. A partitioned survival model was developed to compare costs and effectiveness of first-line (CDK4/6i-first) versus second-line (CDK4/6i-second) CDK4/6 inhibitor strategies among Chinese women with advanced HR+/HER2- breast cancer. Model inputs…

Effect of Nitisinone on Aortic Stenosis Disease Progression in Patients With Alkaptonuria: An Analysis of the Suitability of Nitisinone in Alkaptonuria (SONIA) 2 Study.

Bruce C, Meenamkuzhy-Hariharan P, Hussain S, et al.· Cureus· 2025

Background and aim Alkaptonuria (AKU) is a rare metabolic disorder characterised by the accumulation of homogentisic acid (HGA). Deposition of HGA in the aortic valve leading to progressive aortic stenosis is a serious complication. Nitisinone has been shown to improve morbidity and slow disease progression in AKU, but the effects of this treatment on aortic stenosis progression have not yet been described. The objective of this study was to evaluate whether treatment with nitisinone attenuated the progression of aortic stenosis, as assessed by peak trans-aortic valve pressure (P), in patient…

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Wortelboer N, van Ommen-Nijhof A, Konings IR, et al.· JAMA Oncol· 2026RCT

Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are widely used in hormone receptor (HR)-positive, ERBB2-negative advanced breast cancer (ABC). The SONIA trial evaluates the optimal timing of CDK4/6i administration, either in first-line or second-line setting. To determine whether first-line CDK4/6i use is superior to second-line use in terms of overall survival (OS) and to provide an updated analysis of the primary end point of progression-free survival (PFS) after 2 lines of therapy. The phase 3 SONIA randomized clinical trial is a multicenter tria…

See all on PubMed